Case Type: Mergers & Acquisitions

Redwire Corporation (NYSE: RDW), relating to the proposed merger with Edge Autonomy Ultimate Holdings, LP. Under the terms of the agreement, Redwire will acquire Edge Autonomy using $150M in cash and $775M in shares of Redwire common stock.

180 Degree Capital Corp. (Nasdaq: TURN), relating to the proposed merger with Mount Logan Capital Inc. Under the terms of the agreement, the estimated post-merger shareholder ownership would be approximately 40% for current 180 Degree Capital shareholders.

Amplify Energy Corp. (NYSE: AMPY), relating to the proposed merger with Juniper Capital. Under the terms of the agreement, Amplify shareholders will retain approximately 61% of Amplify’s outstanding equity.

ReShape Lifesciences Inc. (Nasdaq: RSLS), relating to the proposed merger with Vyome Therapeutics, Inc. Under the terms of the agreement, ReShape and Vyome will combine in an all-stock transaction, with ReShape stockholders owning approximately 11.1% of the combined company.

Edible Garden AG Incorporated (Nasdaq: EDBL), relating to the proposed merger with Narayan d.o.o. Under the terms of the non-binding letter of intent, in consideration for 100% of the share capital of Narayan, Edible Garden will issue to the Narayan shareholders shares of Edible Garden common stock.

Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), relating to the proposed merger with Decoy Therapeutics, Inc. Under the terms of the agreement, Salarius stockholders would own approximately 14% of the outstanding shares of the combined company.

H&E Equipment Services, Inc. (Nasdaq: HEES), relating to the proposed merger with Herc Holdings Inc. Under the terms of the agreement, H&E shareholders will receive $78.75 in cash and 0.1287 shares of Herc common stock for each share they own. H&E’s shareholders will own approximately 14.1% of the combined company.

Enfusion, Inc. (NYSE: ENFN), relating to the proposed merger with Clearwater Analytics. Under the terms of the agreement, Enfusion shareholders will receive $5.85 per share in cash and $5.40 per share in Clearwater Class A Common Stock.

Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), relating to the proposed merger with Johnson & Johnson. Under the terms of the agreement, Johnson & Johnson will acquire all outstanding shares of Intra-Cellular Therapies for a payment of $132.00 per share in cash.

CNB Financial Corporation (Nasdaq: CCNE), relating to the proposed merger with ESSA Bancorp, Inc. Under the terms of the agreement, ESSA shareholders will receive 0.8547 shares of CNB common stock for each outstanding share of ESSA common stock.